In this Issue
Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer
Songtao Cheng; Gang Wang; Yejinpeng Wang; Liwei Cai; Kaiyu Qian; Lingao Ju; Xuefeng Liu; Yu Xiao; Xinghuan Wang
Clinical Science (15 August 2019) 133 (15): 1745–1758.
Mitochondrial ROS-induced lysosomal dysfunction impairs autophagic flux and contributes to M1 macrophage polarization in a diabetic condition
Yujia Yuan; Younan Chen; Tianqing Peng; Lan Li; Wuzheng Zhu; Fei Liu; Shuyun Liu; Xingxing An; Ruixi Luo; Jingqiu Cheng; Jingping Liu; Yanrong Lu
Clinical Science (15 August 2019) 133 (15): 1759–1777.
Cover ImageProgressive nephritis in NZB/W F1 mice, a murine model for lupus nephritis, is accompanied by progressive fibrosis characterised by increased deposition of collagen in the kidney. In the latest issue of Clinical Science (volume 133, issue 15), Zhang et al. describe experiments comparing mycophenolate and rapamycin in the treatment of murine lupus nephritis, focusing on kidney fibrosis which is a harbinger of kidney failure. Mycophenolate is a standard-of-care treatment for patients with lupus nephritis; and rapamycin is a drug currently used in the prevention of kidney transplant rejection, with anecdotal experience in patients with lupus nephritis. The cover image demonstrates comparable efficacy between mycophenolate and rapamycin in reducing the histopathologic severity of nephritis and collagen accumulation (blue colouration, Masson's trichrome staining).